Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission), 42706 [2017-19186]
Download as PDF
<![CDATA[
42706
Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Notices
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Overview of This Information
Collection
1. Type of Information Collection
(check justification or form 83):
Revision of a currently approved
collection.
2. The Title of the Form/Collection:
Application and Permit for Temporary
Importation of Firearms and
Ammunition By Nonimmigrant Aliens.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Form number (if applicable): ATF F
6NIA (5330.3D).
Component: Bureau of Alcohol,
Tobacco, Firearms and Explosives, U.S.
Department of Justice.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Individuals or households.
Other (if applicable): None.
Abstract: The form allows
nonimmigrant aliens to temporarily
import firearms and ammunition into
the United States for hunting or other
sporting purposes.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: An estimated 15,000
respondents will utilize the form, and it
will take each respondent
approximately 30 minutes to complete
the form.
6. An estimate of the total public
burden (in hours) associated with the
collection: The estimated annual public
burden associated with this collection is
7,500 hours which is equal to 15,000
(the total # of respondents) * .5 (30
minutes).
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., 3E.405A,
Washington, DC 20530.
VerDate Sep<11>2014
16:34 Sep 08, 2017
Jkt 241001
Dated: September 6, 2017.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2017–19132 Filed 9–8–17; 8:45 am]
BILLING CODE 4410–FY–P
public at the meeting. Requests to
accommodate disabilities with respect
to livestreaming or otherwise should
also be sent to that email address,
preferably at least 10 days prior to the
meeting to allow time for processing.
The
Commission was established in
accordance with E.O. 13784 of March
29, 2017, the Commission’s charter, and
the provisions of the Federal Advisory
Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and
recommendations for the President
regarding drug issues. The Executive
Order, charter, and information on the
Members of the Commission are
available on ONDCP’s Web site. The
Commission will function solely as an
advisory body and will make
recommendations regarding policies
and practices for combating drug
addiction with particular focus on the
current opioid crisis in the United
States. The Commission’s final report is
due October 1, 2017 unless there is an
extension. Per E.O. 13784, the
Commission shall:
a. Identify and describe the existing
Federal funding used to combat drug
addiction and the opioid crisis;
b. assess the availability and
accessibility of drug addiction treatment
services and overdose reversal
throughout the country and identify
areas that are underserved;
c. identify and report on best practices
for addiction prevention, including
healthcare provider education and
evaluation of prescription practices,
collaboration between State and Federal
officials, and the use and effectiveness
of State prescription drug monitoring
programs;
d. review the literature evaluating the
effectiveness of educational messages
for youth and adults with respect to
prescription and illicit opioids;
e. identify and evaluate existing
Federal programs to prevent and treat
drug addiction for their scope and
effectiveness, and make
recommendations for improving these
programs; and
f. make recommendations to the
President for improving the Federal
response to drug addiction and the
opioid crisis.
SUPPLEMENTARY INFORMATION:
EXECUTIVE OFFICE OF THE
PRESIDENT
Office of National Drug Control Policy
Notification of a Public Meeting of the
President’s Commission on Combating
Drug Addiction and the Opioid Crisis
(Commission)
Office of National Drug Control
Policy (ONDCP), Executive Office of the
President.
ACTION: Notice of meeting.
AGENCY:
ONDCP announces the third
meeting of the President’s Commission
on Combating Drug Addiction and the
Opioid Crisis to advance the
Commission’s work on drug issues and
the opioid crisis per Executive Order
13784. The meeting will consist of
statements to the Commission from
invited government, nonprofit, and
business organizations regarding
Innovative Pain Management and
Prevention Measures for Diversion
followed by discussion of the issues
raised.
SUMMARY:
The Commission meeting will be
held on Wednesday September 27, 2017
from 12:30 p.m. until approximately
2:30 p.m. (Eastern Time).
ADDRESSES: The meeting will be held at
the Eisenhower Executive Office
Building, Room 350, in the Executive
Office of the President in Washington,
DC. It will be open to the public through
livestreaming on https://
www.whitehouse.gov/live.
FOR FURTHER INFORMATION CONTACT:
General information concerning the
Commission and its meetings can be
found on ONDCP’s Web site at https://
www.whitehouse.gov/ondcp/presidentscommission. Any member of the public
who wishes to obtain information about
the Commission or its meetings that is
not already on ONDCP’s Web site or
who wishes to submit written comments
for the Commission’s consideration may
contact Michael Passante, Designated
Federal Officer (DFO) via email at
commission@ondcp.eop.gov or
telephone at (202) 395–6709. Please
note that ONDCP may post such written
comments publicly on our Web site,
including names and contact
information that are submitted. There
will not be oral comments from the
DATES:
PO 00000
Frm 00067
Fmt 4703
Sfmt 9990
Dated: September 6, 2017.
Michael Passante,
Deputy General Counsel, Designated Federal
Officer.
[FR Doc. 2017–19186 Filed 9–8–17; 8:45 am]
BILLING CODE 3280–F5–P
E:\FR\FM\11SEN1.SGM
11SEN1
]]>Agencies
[Federal Register Volume 82, Number 174 (Monday, September 11, 2017)]
[Notices]
[Page 42706]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19186]
=======================================================================
-----------------------------------------------------------------------
EXECUTIVE OFFICE OF THE PRESIDENT
Office of National Drug Control Policy
Notification of a Public Meeting of the President's Commission on
Combating Drug Addiction and the Opioid Crisis (Commission)
AGENCY: Office of National Drug Control Policy (ONDCP), Executive
Office of the President.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: ONDCP announces the third meeting of the President's
Commission on Combating Drug Addiction and the Opioid Crisis to advance
the Commission's work on drug issues and the opioid crisis per
Executive Order 13784. The meeting will consist of statements to the
Commission from invited government, nonprofit, and business
organizations regarding Innovative Pain Management and Prevention
Measures for Diversion followed by discussion of the issues raised.
DATES: The Commission meeting will be held on Wednesday September 27,
2017 from 12:30 p.m. until approximately 2:30 p.m. (Eastern Time).
ADDRESSES: The meeting will be held at the Eisenhower Executive Office
Building, Room 350, in the Executive Office of the President in
Washington, DC. It will be open to the public through livestreaming on
https://www.whitehouse.gov/live.
FOR FURTHER INFORMATION CONTACT: General information concerning the
Commission and its meetings can be found on ONDCP's Web site at https://www.whitehouse.gov/ondcp/presidents-commission. Any member of the
public who wishes to obtain information about the Commission or its
meetings that is not already on ONDCP's Web site or who wishes to
submit written comments for the Commission's consideration may contact
Michael Passante, Designated Federal Officer (DFO) via email at
commission@ondcp.eop.gov or telephone at (202) 395-6709. Please note
that ONDCP may post such written comments publicly on our Web site,
including names and contact information that are submitted. There will
not be oral comments from the public at the meeting. Requests to
accommodate disabilities with respect to livestreaming or otherwise
should also be sent to that email address, preferably at least 10 days
prior to the meeting to allow time for processing.
SUPPLEMENTARY INFORMATION: The Commission was established in accordance
with E.O. 13784 of March 29, 2017, the Commission's charter, and the
provisions of the Federal Advisory Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and recommendations for the President
regarding drug issues. The Executive Order, charter, and information on
the Members of the Commission are available on ONDCP's Web site. The
Commission will function solely as an advisory body and will make
recommendations regarding policies and practices for combating drug
addiction with particular focus on the current opioid crisis in the
United States. The Commission's final report is due October 1, 2017
unless there is an extension. Per E.O. 13784, the Commission shall:
a. Identify and describe the existing Federal funding used to
combat drug addiction and the opioid crisis;
b. assess the availability and accessibility of drug addiction
treatment services and overdose reversal throughout the country and
identify areas that are underserved;
c. identify and report on best practices for addiction prevention,
including healthcare provider education and evaluation of prescription
practices, collaboration between State and Federal officials, and the
use and effectiveness of State prescription drug monitoring programs;
d. review the literature evaluating the effectiveness of
educational messages for youth and adults with respect to prescription
and illicit opioids;
e. identify and evaluate existing Federal programs to prevent and
treat drug addiction for their scope and effectiveness, and make
recommendations for improving these programs; and
f. make recommendations to the President for improving the Federal
response to drug addiction and the opioid crisis.
Dated: September 6, 2017.
Michael Passante,
Deputy General Counsel, Designated Federal Officer.
[FR Doc. 2017-19186 Filed 9-8-17; 8:45 am]
BILLING CODE 3280-F5-P
